Study of the efficacy and safety of the combination of rituximab and CMC544 with rituximab, gemcitabine and oxaliplatine in diffuse large B-cell lymphoma at first or second relapse.

Phase 1

Active, not recruiting

• Conditions: CD20 and CD22 positive diffuse large B-cell lymphoma in first or second relapse or refractory to first and/or second line treatment; Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]; MedDRA version: 17.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2011-003849-18-BE
• Lead Sponsor: YSARC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09-26
• Last Update Posted: 8 August 2016

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

- Histologically documented CD20 and CD22 positive diffuse large B-cell lymphoma, according to WHO classification. Prior CD20 and CD22 immunophenotyping is acceptable. If such prior documentation is not available, then the immunophenotype of the current disease must be documented by fine-needle aspirate or biopsy or by circulating CD20 and CD22 positive non-Hodgkin lymphoma (NHL) cells from peripheral blood during screening. In case of relapse or partial response the disease must be histologically or cytologically proven.
Upon registration the anapath report confirming the diagnosis, must be available.
During the trial the tumor tissue biopsy must be made available for confirmation of the disease.
- In first or second relapse or refractory to first and/or second line treatment. Refractory is defined as less than PR to a prior rituximab containing regimen or relapse within 6 months of the last dose of a prior rituximab containing regimen.
- Not eligible for autologous transplantation.
- Previously treated with a chemotherapy regimen containing anthracyclines and rituximab.
- Aged 18 - 80 years.
- ECOG performance status 0 to 2.
- Minimum life expectancy of 3 months.
- Signed written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 32
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 8

Exclusion Criteria

- Burkitt, mantle cell and T-cell lymphomas.
- Central nervous system or meningeal involvement by the lymphoma.
- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.
- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.
- Nitrosurea or mitomycin C administration within 6 weeks prior to study start.
- Major debulking surgery within 3 weeks of treatment.
- Any of the following lab abnormalities (unless related to the lymphoma or bone marrow infiltration):
– Absolute neutrophil count (ANC) < 1.500/µL (1,5.109/L).
– Platelet count < 100.000/µL (100.109/L).
– Creatinine level > 150 µmol/L (1,7 mg/dL) or 1,5 – 2,0x ULN.
– Total bilirubin level > 30 µmol/L (1,8 mg/dL) or 1,5x ULN.
– Serum AST/SGOT or ALT/SGPT >2,5x ULN.
- Documented infection with HIV, active hepatitis B or C infection.
- Any serious active disease or co-morbid medical condition that, according to the investigator’s decision, will substantially increase the risk associated with the subject’s participation in the study. Prior history of malignancies other than lymphoma with the exception of non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or stage 0 (in situ) cervical carcinoma unless the subject has been disease-free for 5 or more years.
- LVEF less than 50% (measured by echocardiography or scintigraphy).
- Previous myocardial infarction or pulmonary hypertension within 6 months before the first dose of investigational product.
- Congestive heart failure NYHA stage III or IV
- Known chronic liver disease (eg. Cirrhosis) or suspected alcohol abuse.
- Pregnant or lactating females
- Men and women who are biologically capable of having children not willing to use an adequate method of birth control during the study and up to 18 months after the last dose of investigational product.
- Adult patient unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified